G1 Therapeutics Inc (GTHX)
$4.17
Insights on G1 Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 12.3M → 14.87M (in $), with an average increase of 17.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -18.20M → -10.87M (in $), with an average increase of 67.4% per quarter
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 326.9%
Performance
- $4.07$4.28$4.17
2.52%
Downside
Day's Volatility :5.02%
Upside
2.57%
- $1.08$5.00$4.17
74.1%
Downside
52 Weeks Volatility :78.4%
Upside
16.6%
Returns
| Period | G1 Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 20.9% | -0.7% | 0.0% |
6 Months | 231.78% | 6.6% | 0.0% |
1 Year | 52.86% | 3.7% | -1.5% |
3 Years | -81.19% | 14.0% | -21.8% |
Highlights
Market Capitalization | 213.0M |
Book Value | $0.68 |
Earnings Per Share (EPS) | -0.93 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.5 |
Profit Margin | -58.13% |
Operating Margin TTM | -60.04% |
Return On Assets TTM | -15.96% |
Return On Equity TTM | -92.13% |
Revenue TTM | 82.5M |
Revenue Per Share TTM | 1.6 |
Quarterly Revenue Growth YOY | 45.1% |
Gross Profit TTM | 47.6M |
EBITDA | -39.0M |
Diluted Eps TTM | -0.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.69 |
EPS Estimate Next Year | -0.45 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.27 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 103.84%
Technicals Summary
Sell
Neutral
Buy
G1 Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 G1 Therapeutics Inc | 33.33% | 231.78% | 52.86% | -81.19% | -75.97% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
G1 Therapeutics Inc | NA | NA | 0.0 | -0.69 | -0.92 | -0.16 | NA | 0.68 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
G1 Therapeutics Inc | Buy | $213.0M | -75.97% | NA | -58.13% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
Vanguard Group Inc
3.80%Susquehanna International Group, LLP
3.02%BlackRock Inc
1.30%Renaissance Technologies Corp
1.21%Jacobs Levy Equity Management, Inc.
1.10%Raymond James & Associates
1.08%
Corporate Announcements
G1 Therapeutics Inc Earnings
G1 Therapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
Organization | G1 Therapeutics Inc |
Employees | 100 |
CEO | Mr. John E. Bailey Jr. |
Industry | Health Technology |
